1. Home
  2. GKOS vs MMS Comparison

GKOS vs MMS Comparison

Compare GKOS & MMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GKOS
  • MMS
  • Stock Information
  • Founded
  • GKOS 1998
  • MMS 1975
  • Country
  • GKOS United States
  • MMS United States
  • Employees
  • GKOS N/A
  • MMS N/A
  • Industry
  • GKOS Medical/Dental Instruments
  • MMS Business Services
  • Sector
  • GKOS Health Care
  • MMS Consumer Discretionary
  • Exchange
  • GKOS Nasdaq
  • MMS Nasdaq
  • Market Cap
  • GKOS 5.4B
  • MMS 4.8B
  • IPO Year
  • GKOS 2015
  • MMS 1997
  • Fundamental
  • Price
  • GKOS $91.09
  • MMS $82.34
  • Analyst Decision
  • GKOS Strong Buy
  • MMS Buy
  • Analyst Count
  • GKOS 13
  • MMS 1
  • Target Price
  • GKOS $122.08
  • MMS $90.00
  • AVG Volume (30 Days)
  • GKOS 1.6M
  • MMS 463.3K
  • Earning Date
  • GKOS 10-29-2025
  • MMS 11-20-2025
  • Dividend Yield
  • GKOS N/A
  • MMS 1.43%
  • EPS Growth
  • GKOS N/A
  • MMS 12.65
  • EPS
  • GKOS N/A
  • MMS 5.37
  • Revenue
  • GKOS $469,820,000.00
  • MMS $5,428,731,000.00
  • Revenue This Year
  • GKOS $30.89
  • MMS $3.80
  • Revenue Next Year
  • GKOS $24.36
  • MMS $2.20
  • P/E Ratio
  • GKOS N/A
  • MMS $15.66
  • Revenue Growth
  • GKOS 30.38
  • MMS 3.40
  • 52 Week Low
  • GKOS $73.16
  • MMS $63.77
  • 52 Week High
  • GKOS $163.71
  • MMS $92.63
  • Technical
  • Relative Strength Index (RSI)
  • GKOS 60.41
  • MMS 36.56
  • Support Level
  • GKOS $80.91
  • MMS $82.09
  • Resistance Level
  • GKOS $102.80
  • MMS $84.36
  • Average True Range (ATR)
  • GKOS 4.63
  • MMS 1.96
  • MACD
  • GKOS 1.07
  • MMS -0.26
  • Stochastic Oscillator
  • GKOS 56.85
  • MMS 21.43

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About MMS Maximus Inc.

Maximus Inc designs, develops, and delivers programs, enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments; U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.

Share on Social Networks: